Literature DB >> 19148809

Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation.

Ryosuke Tateishi1, Shuichiro Shiina, Takamasa Ohki, Takahisa Sato, Ryota Masuzaki, Jun Imamura, Eriko Goto, Tadashi Goto, Hideo Yoshida, Shuntaro Obi, Shinpei Sato, Fumihiko Kanai, Haruhiko Yoshida, Masao Omata.   

Abstract

BACKGROUND: Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is ordinarily indicated for those with three or fewer nodules, none of which exceeds 3 cm in diameter. This study investigated whether an apparent threshold exists in the diameter and number of nodules in terms of the prognosis of patients with HCC.
METHODS: We enrolled 663 naïve patients with HCC who were treated with RFA at our hospital between 1999 and 2005. We analyzed the patients' prognosis using multivariate Cox proportional regression with the diameter and number of nodules as covariates and Child-Pugh class as a stratification factor. The diameter and number were categorized as <or=2.0, 2.1-3.0, 3.1-4.0, 4.1-5.0, and >5 cm and 1, 2-3, 4-5, and >5, respectively.
RESULTS: The adjusted hazard ratio of patients whose largest nodule was <or=2.0, 2.1-3.0, 3.1-4.0, 4.1-5.0, and >5 cm was 1, 1.51, 2.56, 2.25, and 2.71, respectively. The adjusted hazard ratio of patients with one, two or three, four or five, and more than five nodules was 1, 1.35, 1.70, and 2.12, respectively. Therefore, patients with three or fewer nodules, none of which exceeds 5 cm in diameter, have a 5-year survival of 40%.
CONCLUSIONS: The prognosis of the patients worsened gradually as the diameter and number of nodules increased. No apparent threshold in the diameter or number of HCC nodules was detected. RFA can be applied beyond the conventional indications.

Entities:  

Mesh:

Year:  2009        PMID: 19148809     DOI: 10.1007/s00535-008-2247-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  34 in total

1.  Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.

Authors:  Ryosuke Tateishi; Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Yukihiro Koike; Tomonori Fujishima; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

2.  Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations.

Authors:  Takuma Teratani; Haruhiko Yoshida; Shuichiro Shiina; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Norio Mine; Yuji Kondo; Takao Kawabe; Masao Omata
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

3.  Radiation therapy for portal venous invasion by hepatocellular carcinoma.

Authors:  Keiichi Nakagawa; Hideomi Yamashita; Kenshiro Shiraishi; Naoki Nakamura; Masao Tago; Hiroshi Igaki; Yoshio Hosoi; Shuichiro Shiina; Masao Omata; Masatoshi Makuuchi; Kuni Ohtomo
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

4.  Trends in primary liver cancer.

Authors:  S Deuffic; T Poynard; L Buffat; A J Valleron
Journal:  Lancet       Date:  1998-01-17       Impact factor: 79.321

5.  Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.

Authors:  S A Curley; F Izzo; L M Ellis; J Nicolas Vauthey; P Vallone
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

6.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

7.  Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study.

Authors:  Guan-Tarn Huang; Po-Huang Lee; Yuk-Ming Tsang; Ming-Yang Lai; Pei-Ming Yang; Rey-Heng Hu; Pei-Jer Chen; Jia-Horng Kao; Jin-Chuan Sheu; Cha-Ze Lee; Ding-Shinn Chen
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

8.  Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan.

Authors:  Y Shiratori; S Shiina; M Imamura; N Kato; F Kanai; T Okudaira; T Teratani; G Tohgo; N Toda; M Ohashi
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

9.  Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases.

Authors:  T Higuchi; M Kikuchi; M Okazaki
Journal:  Cancer       Date:  1994-05-01       Impact factor: 6.860

10.  Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.

Authors:  T Livraghi; A Giorgio; G Marin; A Salmi; I de Sio; L Bolondi; M Pompili; F Brunello; S Lazzaroni; G Torzilli
Journal:  Radiology       Date:  1995-10       Impact factor: 11.105

View more
  8 in total

1.  A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.

Authors:  Yuzo Umeda; Hiroaki Matsuda; Hiroshi Sadamori; Hiroyoshi Matsukawa; Takahito Yagi; Toshiyoshi Fujiwara
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

Review 2.  Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.

Authors:  Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Resection and radiofrequency ablation in the treatment of hepatocellular carcinoma: a single-center experience.

Authors:  Koray Karabulut; Federico Aucejo; Hizir Yakup Akyildiz; Allan Siperstein; Eren Berber
Journal:  Surg Endosc       Date:  2011-10-25       Impact factor: 4.584

Review 4.  Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2015-04-08       Impact factor: 11.740

5.  CT-guided Interstitial Brachytherapy of Hepatocellular Carcinoma before Liver Transplantation: an Equivalent Alternative to Transarterial Chemoembolization?

Authors:  Timm Denecke; Lars Stelter; Dirk Schnapauff; Ingo Steffen; Bruno Sinn; Eckart Schott; Ricarda Seidensticker; Gero Puhl; Bernhard Gebauer; Enrique Lopez Hänninen; Peter Wust; Peter Neuhaus; Daniel Seehofer
Journal:  Eur Radiol       Date:  2015-03-04       Impact factor: 5.315

6.  Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial.

Authors:  Takamasa Ohki; Ryosuke Tateishi; Masaaki Akahane; Shuichiro Shiina; Noriyo Yamashiki; Shintaro Mikami; Kenichiro Enooku; Eriko Goto; Ryota Masuzaki; Yuji Kondo; Tadashi Goto; Shinichi Inoo; Kuni Ohtomo; Masao Omata; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Hepatol Int       Date:  2011-08-31       Impact factor: 6.047

Review 7.  Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

8.  CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trial.

Authors:  Takamasa Ohki; Ryosuke Tateishi; Masaaki Akahane; Shintaro Mikami; Masaya Sato; Koji Uchino; Toru Arano; Kenichiro Enooku; Yuji Kondo; Noriyo Yamashiki; Tadashi Goto; Shuichiro Shiina; Haruhiko Yoshida; Yutaka Matsuyama; Masao Omata; Kuni Ohtomo; Kazuhiko Koike
Journal:  Am J Gastroenterol       Date:  2013-04-30       Impact factor: 10.864

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.